Impact of the COVID-19 pandemic on tuberculosis national reference laboratory services in the WHO European Region, March to November 2020

We assessed the impact of COVID-19 on diagnostic services for tuberculosis (TB) by national reference laboratories in the WHO European Region. Of 35 laboratories, 30 reported declines in TB sample numbers, amounting up to >50% of the pre-COVID-19 volumes. Sixteen reported reagent or consumable shortages. Nineteen reallocated resources to SARS-CoV-2 testing, resulting in an overall increase in workload, largely without a concomitant increase in personnel (n=14). This poses a risk to meeting the 2025 milestones of the End TB Strategy.

Here, we set out to expand these early observations on the impact on TB diagnostic services in the WHO European Region from March to November 2020, with a focus on countries with a high burden of multidrug-resistant TB (MDR-TB), defined as being resistant to rifampicin and isoniazid.

Capturing the state of reference laboratory services March to November 2020

An online survey, jointly prepared by the European Laboratory Initiative (ELI) and the WHO Regional Office for Europe Joint TB, HIV and Viral Hepatitis (JTH) programme, was conducted among directors of TB NRL from all countries within the Region. Nine questions addressed the quantitative impact of the pandemic on TB sample numbers, shortages in reagents and consumables, as well as reallocation of TB laboratory infrastructure or staff to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing. Eligible participants were invited by ELI/JTH to complete the survey between December 2020 and April 2021. Participants were blinded towards responses from other laboratories throughout the survey. Results were collected electronically and analysed by ELI/JTH.

In total, 35 of 44 eligible laboratories responded to the survey. The laboratories were located in Albania, Armenia, Azerbaijan, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Denmark, Estonia,
Finland, France, Georgia, Germany, Hungary, Ireland, Italy, Kazakhstan, Kyrgyzstan, Latvia, Moldova, Montenegro, the Netherlands, Poland, Portugal, Romania, Russia (three eligible laboratories), Slovenia, Spain, Sweden, Tajikistan, Turkey, and Uzbekistan. They included 10 reference laboratories from eight of the nine high MDR-TB burden countries in the WHO European Region, comprising the three eligible reference laboratories from Russia [3]. Thirty NRL reported declines in sample numbers received for TB testing ranging from < 25% (n = 21), and 25–50% (8), to > 50% (n = 1) compared with the average pre-COVID-19 testing volume (Figure 1). Declines in sample numbers submitted to the 10 NRL from countries with a high burden of MDR-TB were mostly reported to be < 25% (n = 6). Two laboratories reported declines of 25–50%, and two laboratories reported no decline.

Almost half (n = 16) of the participating laboratories, including three of 10 laboratories from high MDR-TB burden countries, reported to have been affected by reagent or consumable shortages, delayed shipments, or stockouts (Figure 1). Two laboratories reported shortages of > 50% of reagents or consumables.

SARS-CoV-2 testing in tuberculosis reference laboratories

TB diagnostic infrastructures offer high spatial coverage, preexisting supply chains, staff trained to work with airborne pathogens, and the availability of analytical and biosafety equipment. Leveraging the potential of TB laboratories for SARS-CoV-2 testing has therefore been an evident consideration in the laboratory response to the COVID-19 pandemic, particularly in otherwise resource-poor settings. Respective guidance was issued by WHO, the Stop TB Partnership, and others [4-7]. In our survey, 19 of 35 participating laboratories reported having reallocated infrastructure and/or workforce to SARS-CoV-2 testing, including five of 10 laboratories from countries with a high burden of MDR-TB (Figure 2). The extent to which laboratory infrastructure or staff were reassigned to the COVID-19 response varied between < 25% (n = 11), 25–50% (n = 7), and > 50% (n = 1) (Figure 2). Sixteen of the 19 laboratories that reallocated resources to the COVID-19 response confirmed that they had performed laboratory biosafety assessments before handling SARS-CoV-2 samples, and all 19 laboratories reported having conducted specific biosafety training with the involved staff (Figure 2).
Notably, while a large majority of participants reported declines in sample numbers sent for TB diagnostics, the overall workload in the 19 laboratories that reallocated resources to SARS-CoV-2 testing increased by between <25% (n = 12), 25–50% (n = 5), and >50% (n = 2) (Figure 3). Only five of the 19 laboratories involved in the COVID-19 response reported increases in personnel and just eight laboratories reported salary compensations for staff performing SARS-CoV-2 testing in addition to their regular duties (Figure 3). The two laboratories that reported the highest increases in the overall workload were located in countries with a total annual TB incidence rate well above the average of the WHO European Region, pointing to a substantial workload for both diseases at the same time. One of these laboratories reported granting additional payments for the involved personnel but no staff increases, while the other reported the availability of additional human resources without salary compensations.

**Discussion**

Before the start of the COVID-19 pandemic, TB was the leading cause of death because of a single infectious agent, affecting 10 million people in 2019 and causing 1.4 million deaths worldwide [3]. With an overall percentage reduction in the TB incidence rate (new and relapse cases per 100,000 population per year) of 19% between 2015 and 2019, the European Region has almost reached an important milestone of the End TB Strategy (a 20% reduction by 2020) [8]. With a 31% reduction in deaths due to TB during the same period, the WHO European Region has also been on track to reach the 2020 milestone of a 30% reduction in the absolute number of deaths because of TB.
Figure 3
Impact of SARS-CoV-2 testing on overall workload in 19 tuberculosis national reference laboratories (n = 17 countries)

A. To which extent has your laboratory’s overall workload increased due to SARS-CoV-2 testing?

- ↑ by 50%
- ↑ by 25-50%
- ↑ by ≥25%
- Not increased

B. Have your available human resources increased since you commenced with SARS-CoV-2 testing?

- Yes
- No

C. Are staff in your laboratory receiving a salary compensation for performing SARS-CoV-2 testing?

- Yes
- No
- Not applicable

SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.

Only the 19 responses by laboratories that indicated performing SARS-CoV-2 testing in question ‘Has your laboratory or have your staff been repurposed to perform SARS-CoV-2 testing?’ (Figure 2 panel A) are shown.
per year [3]. However, with an estimated 16–18% of all newly diagnosed patients and 45–59% of all previously treated patients having MDR-TB, the Region remains well above the global average of 2–4% and 10–27%, respectively [3]. This situation posed a risk to meeting the ambitious 2025 milestones of the End TB Strategy, particularly in the eastern part of the Region, already prior to the COVID-19 pandemic.

Since the beginning of 2020, the emergence of SARS-CoV-2 has had large health, social, and economic impacts. Two modelling analyses predicted that the annual number of deaths due to TB globally could rise to the levels last seen in 2015 or even 2012 [9,10]. First data released by the StopTB partnership indicate that, as of March 2021, TB services are still impaired in most high burden countries and that a total decline of 1 million cases being diagnosed with TB and enrolled in treatment was observed in nine high burden countries that represent 60% of the global TB burden [11]. Provisional data collected by WHO from 84 countries indicate that an estimated 1.4 million fewer people received care for TB in 2020 than in 2019 [12]. Although additional analyses have been performed addressing the changes in TB notification rates since the onset of the COVID-19 pandemic and its worldwide effects on clinical TB services, few studies have investigated the impact of the pandemic on TB diagnostic services [13-16]. In a WHO survey conducted among 184 National Tuberculosis Programmes, 46% (85/184) respondents reported reallocation of staff at national or subnational level, 28% (52/184) reported reallocation of funding towards the COVID-19 response, and 23% (43/184) reported reallocation of GeneXpert PCR machines for SARS-CoV-2 testing. Notably, the corresponding proportions were considerably higher among a subgroup of 30 countries with particularly high TB burdens (67%, 47%, and 43%, respectively) [3].

This study has some limitations. First, the chosen study period did not cover the second and third COVID-19 waves in full, and personal communications with many of the participating laboratory directors indicate that these may have affected some laboratories even harder than the first wave of the pandemic [18]. Second, the study was limited to reference diagnostic services and did not address any COVID-19 related impact on more peripheral laboratories. Third, we did not address response bias, observation bias or recall bias potentially leading to under- or overreporting of changes in sample numbers, workload or compensation efforts. Finally, this survey relied exclusively on estimates by the laboratory leadership in order to facilitate a rapid assessment of the situation. Studies analysing actual sample numbers would be desirable to further objectivise the impact of the COVID-19 pandemic on TB diagnostic services in the Region.

Conclusions
A growing body of evidence suggests that the collision of the COVID-19 pandemic with other global healthcare threats such as HIV, viral hepatitis, antimicrobial resistance and TB puts at risk many of the achievements made in the fight against these diseases during recent years. For TB, our data demonstrate that reference diagnostic services throughout the WHO European Region were strongly affected by the COVID-19 pandemic in terms of lower sample numbers, reagent shortages and by supporting the important need for SARS-CoV-2 testing through reallocation of resources. With respect to the latter, decision makers at all levels will need to keep ensuring preparedness against novel pandemic diseases in public health laboratories by providing adequate staff capacity and infrastructures, and by uninterrupted procurement of essential consumables and reagents.

Investigators
Ana Avellón, Zamira Baydulloeva, Vladimir Chulanov, Daniela Maria Cirillo, Dmitry Kireev, Claudio U Köser, Stefan Niemann, Ecaterina Noroc, Roger Paredes, Rob Schuurman, Elina V Sevastyanova, Daniel Simões, Alena Skrahina, Maja Stanojevic.

Acknowledgements
The authors wish to thank all participants that took part in this survey. We wish to thank Eduard Kabasakalıyan for critical review of the survey. Financial support for this work has been provided by the German Government.

Conflict of interest
FM and FD are consultants for the WHO Regional Office for Europe at the time of reporting. All other authors have no conflicts of interest to declare.
Authors’ contributions

The survey was developed by SE with contributions by NS, GK, IF, FD and reviewed by AY and GK. FPM and SE analyzed the data and wrote the first draft of the manuscript. The European Laboratory Initiative on TB, HIV and Viral Hepatitis expert core group provided comments on the manuscript and helped disseminate its findings in its network.

References

1. Nikolayevskyy V, Holicky Y, van Soolingen D, van der Werf M, Ködmón C, Surova E, et al. ERLTB-Net-2 study participants. Impact of the COVID-19 pandemic on tuberculosis laboratory services in Europe. Eur Respir J. 2020;56(4):2002665. https://doi.org/10.1183/13993003.02665-2020 PMID: 32703780

2. Simões D, Stengaard AR, Combs L, Raben D, EuroTEST. Considerations for selection of SARS-CoV-2 diagnostics and potential multiplexing: A perspective to ensure continuity of care for people with TB. Geneva: Stop TB Partnership; 14 May 2020. Available from: http://www.stoptb.org/assets/documents/covid/Considerations for selection of SARS-CoV-2 diagnostics.pdf

3. World Health Organization (WHO). Global Tuberculosis Report 2020. Geneva: WHO; 2020. Available from: https://apps.who.intiris/bitstream/handle/10665/336069/9789240013131-eng.pdf

4. World Health Organization (WHO). Information Note on Tuberculosis and COVID-19. Geneva: WHO. [Accessed: 25 Mar 2021]. Available from: https://www.who.int/news/item/15-12-2020-updated-who-information-note-ensuring-continuity-of-tb-services-during-the-covid-19-pandemic

5. World Health Organization Regional Office for Europe. Rapid communication on the role of the GeneXpert® platform for rapid molecular testing for SARS-CoV-2 in the WHO European Region, March to August 2020. Euro Surveill. 2020;25(4):25. https://doi.org/10.2807/1560-7917.ES.2020.25.47.2001943 PMID: 32423354

6. World Health Organization Regional Office for Europe. Considerations for selection of SARS-CoV-2 diagnostics and potential multiplexing: A perspective to ensure continuity of care for people with TB. Geneva: Stop TB Partnership; 14 May 2020. Available from: http://www.stoptb.org/assets/documents/covid/Considerations for selection of SARS-CoV-2 diagnostics.pdf

7. Homolka S, Paulowski L, Andres S, Hillemann D, Jou R, Günther T, et al. Two Pandemics, One Challenge-Leveraging Molecular Test Capacity of Tuberculosis Laboratories for Rapid COVID-19 Case-Finding. Emerg Infect Dis. 2020;26:2549-54. https://doi.org/10.3201/eid2611.200389

8. World Health Organization (WHO). Information Note on Tuberculosis and COVID-19. Geneva: WHO. [Accessed: 25 Mar 2021]. Available from: https://www.euro.who.int/en/health-topics/diseases/tuberculosis/publications/2020/rapid-communication-on-the-role-of-the-geneexpert-platform-for-rapid-molecular-testing-for-sars-cov-2-in-the-who-european-region-2020-produced-by-who-europe

9. Glaziou P. Predicted impact of the COVID-19 pandemic on global tuberculosis deaths in 2020. medRxiv. 4 May 2020. https://doi.org/10.1101/2020.04.28.20079582

10. Cilloni L, Fu H, Vesga JF, Dowdy D, Pretorius C, Ahmedov S, et al. The potential impact of the COVID-19 pandemic on the tuberculosis epidemic: a modelling analysis. EclinicalMedicine. 2020;28:100603. PMID: 33134905

11. Stop TB Partnership. One year on, new data show global impact of Covid-19 on TB epidemic is worse than expected. Geneva: Stop TB Partnership; 18 Mar 2021. Press release. Available from: http://www.stoptb.org/webadmin/cms/docs/Release%20of%20COVID%20and%20TB%202021%20report%20draft%2016%20March_FINAL.pdf

12. World Health Organization (WHO). Impact of the COVID-19 pandemic on TB detection and mortality in 2020. Geneva: WHO; 22 Mar 2021. Available from: https://www.who.int/publications/m/item/impact-of-the-covid-19-pandemic-on-tb-detection-and-mortality-in-2020

13. Migliori GB, Thong PM, Akkerman O, Alffenaar JW, Alvarez-Navascués F, Assao-Neino MM, et al. Worldwide Effects of Coronavirus Disease Pandemic on Tuberculosis Services, January-April 2020. Emerg Infect Dis. 2020;26(11):2705-12. https://doi.org/10.3201/eid2611.200316 PMID: 32917293

14. Magro P, Formenti B, Marchese V, Guilletta M, Tomasoni LR, Calgaris S, et al. Impact of the SARS-CoV-2 epidemic on tuberculosis treatment outcome in Northern Italy. Eur Respir J. 2020;56(4):2002665. https://doi.org/10.1183/13993003.02665-2020 PMID: 32703780

15. Fei H, Yinlin X, Hui C, Ni W, Xin D, Wei C, et al. The impact of the COVID-19 epidemic on tuberculosis control in China. Lancet Regional Health - West Pacific 2020;3:100032. http://dx.doi.org/10.1016/j.lanwpc.2020.100032

16. Graciaa DS, Kemperk RR, Sanikidze E, Tukvadze S, Mikashvili L, Aspindzelashvili R, et al. TB research amidst the COVID-19 pandemic. Int J Tuberc Lung Dis. 2021;25(3):167-70. https://doi.org/10.5588/ijtld.20.0792

17. McQuaid CF, McCreesh N, Read JM, Sumner T, Houben RMG, White RG, et al., CMMID COVID-19 Working Group. The potential impact of COVID-19-related disruption on tuberculosis burden. Eur Respir J. 2020;56(2):2002718. https://doi.org/10.1183/13993003.01718-2020 PMID: 32537874

18. World Health Organization (WHO). WHO Coronavirus (COVID-19) Dashboard. Geneva: WHO. [Accessed: 25 Mar 2021]. Available from: https://covid19.who.int/

License, supplementary material and copyright

This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence and indicate if changes were made.

Any supplementary material referenced in the article can be found in the online version.

This article is copyright of the authors or their affiliated institutions, 2021.